Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2007 August 1; 117(8): 2225–2232.
Published online 2007 August 1. doi:  10.1172/JCI31659
PMCID: PMC1934585

Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy


Recent reports have challenged the notion that retroviruses and retroviral vectors integrate randomly into the host genome. These reports pointed to a strong bias toward integration in and near gene coding regions and, for gammaretroviral vectors, around transcription start sites. Here, we report the results obtained from a large-scale mapping of 572 retroviral integration sites (RISs) isolated from cells of 9 patients with X-linked SCID (SCID-X1) treated with a retrovirus-based gene therapy protocol. Our data showed that two-thirds of insertions occurred in or very near to genes, of which more than half were highly expressed in CD34+ progenitor cells. Strikingly, one-fourth of all integrations were clustered as common integration sites (CISs). The highly significant incidence of CISs in circulating T cells and the nature of their locations indicate that insertion in many gene loci has an influence on cell engraftment, survival, and proliferation. Beyond the observed cases of insertional mutagenesis in 3 patients, these data help to elucidate the relationship between vector insertion and long-term in vivo selection of transduced cells in human patients with SCID-X1.


Retroviruses have been used as efficient gene-delivery vehicles in several gene therapy trials because they integrate stably into the genome, allowing the genetic correction of stem cells, potentially for the entire lifespan of the affected individual (13). The availability of the complete human genome sequence has made possible large-scale sequence-based surveys of retroviral integration sites (RISs), which have strongly challenged the notion that retrovirus vector integration may be a semirandom event (4, 5). Schroeder et al. investigated targeting of HIV and HIV-based vectors in a human lymphoid cell line (SupT1) and found that genes were favored integration targets (6). Similarly, Wu et al. examined targeting of murine leukemia virus (MLV) in human HeLa cells and found that MLV strongly favored integration in transcriptional units, with integration focusing near the start of transcription (7). This nonrandom distribution of integrations has been confirmed by Laufs et al. in human bone marrow–repopulating cells in mouse xenografts (8).

A comparative analysis of human primary cell types and cell lines transduced with HIV-1–, avian sarcoma leukemia virus– (ASLV-), or MLV-based vectors showed that each vector type produces a unique pattern of RIS distribution in the human genome (9). These analyses revealed a significant association between integration target sites and transcriptional profiling for HIV-1, but not for ASLV or MLV (9). Thus, the statistics of the integration process of retroviruses, lentiviruses, and derived vectors suggest that a more specific mechanism — e.g., active tethering of the preintegration complex to DNA motifs, DNA binding factors, or other connections to the gene activation or expression status of target cells — are of influence beyond the accessibility of the euchromatin (1012). In line with this hypothesis, a comparative analysis of retrovirus integration and gene expression status demonstrated reduced integration in genomic sites with highly active transcription (13). A large-scale mapping of RISs in gene-modified T lymphocytes from leukemic patients after allogeneic stem cell transplantation has shown that retroviral vectors integrated preferentially in genes expressed during transduction and that integrations can deregulate gene expression, albeit without obvious side effects (14).

Of the published large-scale in vitro integration site studies, none followed the possible selective advantage induced by virus or vector integration for an individual transduced cell over time. Interestingly, an analysis of MLV retrovirus and SIV lentivirus integration sites in a preclinical nonhuman primate model discovered the presence of common integration sites (CISs) in transcriptional units (15). Recent studies on transduced CD34+ cells have further demonstrated that vector integration is indeed nonrandom, often clustered, and potentially capable of inducing immortalization in vitro, clonal dominance in vivo, or even leukemogenesis in vivo (1618). Insertion in human gene-modified T lymphocytes occurred preferentially at the transcription start site (TSS), but only a low incidence of CIS insertion was found (14).

Recurrent integration in specific gene loci strongly indicates that the insertion has provided a nonrandom growth or survival advantage to the affected target cell clones (17, 18). Our recent observation in a clinical gene therapy trial for chronic granulomatous disease that cell clones with integrations in MDS1/EVI1, PRDM16, or SETBP1 drove a 3- to 4-fold in vivo expansion of the gene-corrected myeloid cell pool emphasizes the importance of analyzing the influence of the integration sites present in transduced cells and their clonal progeny in current gene therapy trials aimed at curing disorders of the myeloid or lymphoid blood cell compartment (19). The occurrence of a lymphoproliferative disease in 3 of our 9 patients showed the biological relevance the integration of replication-defective retroviral vectors may have (20).

Here we demonstrated, by high-throughput integration site analysis and sequencing performed on CD34+ transduced cells and sorted peripheral blood cell samples obtained from patients of the first X-linked SCID (SCID-X1) gene therapy trial, that integration of retroviral vectors took place preferentially in gene coding regions, was skewed to the transcriptional start site (TSS) of genes, and was significantly correlated with the gene expression pattern of the gene-corrected cell population. Most strikingly, the significant clustering of distinct cellular integration events hitting CISs in different circulating lymphocytes indicates that in vivo selection of transduced cells in the clinical setting occurs in relation to vector insertion and may critically influence an individual cell’s repopulation and proliferation capacity.


Distribution analysis of retrovirus vector insertions in patients’ mature blood cells.

To study the characteristics of retroviral insertion in clinical common γ chain (γc) gene correction, a high-throughput analysis of insertion sites was conducted by linear amplification–mediated PCR (LAM-PCR) (2123) on the DNA of whole blood leukocytes (554 sites) and purified peripheral blood T cells (CD3+), granulocytes (CD15+), and monocytes (CD14+; a total of 18 sites) collected 4 to 41 months after the reinfusion of autologous CD34+ cells transduced with a γc encoding retrovirus vector. Concerning the purified cells, 6 of the 18 sites were analyzed in detail previously (21). We retrieved 704 unique insertion site sequences from the 9 analyzed patients, of which 572 (81%; Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI31659DS1) could be mapped unequivocally to the human genome (see Methods). Chromosomal distribution analysis demonstrated that the frequency of insertion sites detected for each of the 23 human chromosomes correlated well with gene content but not with chromosome size (Figure (Figure1A).1A). Insertions were most frequent on chromosome 1, which is the largest chromosome, and least frequent on chromosomes Y and 18. At the same time, the high insertion site frequency on chromosomes 17 and 19 correlated with a higher-than-average number of genes on these chromosomes. Of the 572 unique RISs, 216 (38%) were located within a RefSeq gene, 157 (27%) were within 5 kilobase pairs (kbp) surrounding the TSS, and 356 (62%) were located in the gene coding sequence or less than 10 kbp away (Figure (Figure1,1, B and C, Table Table1,1, and Supplemental Table 1). Insertion data sets of the 3 patients (Pt4, Pt5, and Pt10) that developed a vector-associated T cell acute lymphocytic leukemia–like (T-ALL–like) disorder 30–34 months after gene therapy were analyzed separately (20). Their integration pattern was not found to be significantly different for any of the assessable parameters compared with that of the other patients (Table (Table1). 1).

Figure 1
RIS distribution analysis of engrafted cells.
Table 1
Overall characteristics of RISs found in 9 patients

RIS distribution in transduced CD34+ cells.

To study the influence of the differentiation process on the distribution of insertion sites, we compared the insertion site distribution of transduced pre-injection CD34+ cells (total RISs, 167; mappable RISs, 102) with the profile found in the sorted circulating cell population (total RISs, 191; mappable RISs, 141) of the same patient, Pt4. We did not observe any substantial difference in the frequencies of gene-associated insertions between pre- and posttransplantation cells (49% versus 41%; P = 0.22, χ2 test), of targeting the TSS (within 5 kbp of TSS, 16% versus 26%; P = 0.05), of insertions in the proximity of RefSeq genes and their 10-kbp upstream and downstream vicinity (64% versus 64%; P = 0.98), and of targeting CpG islands (14.7% versus 16.3%; P = 0.73; Figure Figure2). 2).

Figure 2
Comparison of pre- and posttransplant RIS distribution in Pt4.

Vector integration is clustered in CISs.

For the purpose of analyzing high-throughput insertional mutagenesis models in mice, a nonrandom insertion clustering in the form of retrovirus integration into the same genomic locus on 2 or more different cells has been defined as a CIS. A CIS has been shown to be indicative of a nonrandom functional association of the insertion locus with the transformation event (2426). To distinguish random coincidence of neighboring integration from nonrandom CIS formation, we followed a more stringent CIS definition as recently defined by Suzuki et al. (26). We classified CISs only by distance, independently of whether vector integrants were inter- or intragenic. We considered 2, 3, or 4 insertions to be CISs if they fell within a 30-kbp, 50-kbp, or 100-kbp window, respectively. CISs of fifth or higher order were defined by a 200-kbp window. Computer simulations showed that with 572 unique mappable RISs, the average number of randomly occurring second-order CISs (formed by 2 individual integrants) was 3.2 (Supplemental Table 2 and Methods). The null hypothesis that the 102 observed CISs of second order were the result of random clustering could be rejected (estimated P value, 0). No CIS of third order (CISs formed by 3 integrants) or higher was obtained in 10,000 simulation runs.

Of the 572 mappable unique insertions found in blood cells, 122 (21.0%) were part of a CIS (Supplemental Table 3), which is 33-fold the value to be expected under random distribution of the RISs. Of the 47 different loci harboring CISs, 38 (81%) were closer than 30 kbp in distance to the next RefSeq gene. Among the 47 different CIS loci, 11 were known protooncogenes, involved in human chromosomal translocations described in acute leukemia or other forms of cancer: ZNF217, VAV-3, CCND2, LMO2, MDS1, BCL2L1, NOTCH2, SOCS2, RUNX1, RUNX3, and SEPT6. Of these, 9 are well-known transcription factors involved in human hematopoiesis. Fourteen particularly relevant CISs consisted of 3 or more integrants, the majority (10 of 14, 71%) of which localized less than 30 kbp away from genes. Here, protooncogene insertion was found in nearly half (6 of 14, 43%; Table Table2).2). Of note, 3 CISs with 5 (LMO2), 8 (ZNF217), and 9 insertions (CCND2) accounted for 22 (4%) of all independent RISs, suggesting that they confer a strong selective advantage to the cell clones harboring these RISs.

Table 2
CISs of third and higher order detected in patients

Furthermore, we looked for the appearance of clones during the investigation period. Of all CIS clones, 11 of 122 single clones were detected at different time points, whereas only 28 of 450 non-CIS clones were retrieved more than once over time. Most of them appeared between 6 and 13 months and could also be detected later than 30 months, especially in the case of CIS clones. This shows that constant contribution of single clones to normal hematopoiesis plays an important role. The CIS clones are not exclusively responsible for the success of the gene therapy, but they may play an important role.

In the CD34+ cells of Pt4 prior to transplantation, we identified 4 CISs (7.8%) of second order of the 102 unique RISs (Supplemental Table 3), compared with an expected value of 0.03 CISs. Computer simulations only reached a maximum of 3 CISs in 10,000 runs (mean, 0.098; median, 0; standard deviation, 0.31; P = 0; see Methods). This nonrandom integration could indicate that these CISs are particularly accessible, but it was substantially lower than in posttransplantation samples.

We could not distinguish RISs in patients with lymphoproliferation from those without: CISs of third order or higher were spread over these 2 groups of patients. Among the 37% of all integrations derived from lymphoproliferative patients, only 24% of CISs of second order were found, whereas 76% were found in leukemic and healthy patients or only in healthy patients.

RISs are located next to growth-promoting genes.

To characterize the potential biological influence of vector integration on clonal selection, we used the gene ontology (GO) database and related EASE software (see Methods) to classify each gene into defined functional and biological categories. Any category reflects the percentage of a gene category in the GO database. While we did not find any overrepresented gene classes (P < 0.05, Fisher exact test, count threshold of 3) in the transduced pretransplant samples, insertion analysis of engrafted cells showed highly significant overrepresentation of genes involved in phosphorus metabolism, cell survival, kinase activity, transferase activity, receptor signaling, and DNA binding (Table (Table3).3). We did not find any significant differences between patients with and without lymphoproliferation.

Table 3
GO classification

Further comparative analysis showed an accumulation of RISs in or near genes listed in the database of the cancer genome project (; Supplemental Table 1). Of the 356 total genes listed, 31 (9%) vector-targeted genes were known oncogenes. These data underline an integration-related selective advantage of RISs located in the vicinity of growth-promoting genes.

RIS and CIS loci correlate to the gene expression profile of transduced cells.

To test whether the expression of genes is associated with the likelihood of receiving a retrovirus insertion, we analyzed insertions in gene loci as a function of the corresponding gene expression levels in CD34+ cells, relative to the expression levels of all other genes. RISs in engrafted cells were significantly more frequently among the genes with the highest expression levels in CD34+ cells (n = 422; P < 1 × 10–6, Cochran-Armitage test; Figure Figure3A).3A). We further analyzed insertions in pretransplant CD34+ cells from Pt4. Interestingly, although the association was significant, it was less pronounced than that observed in the in vivo setting (n = 83; P = 4.99 × 10–4, Cochran-Armitage test; Figure Figure3B). 3B).

Figure 3
Association between vector integration and gene expression.

CIS location correlated even better with the genes highly expressed in CD34+ cells (Supplemental Table 3). Of 47 CIS genes, 43 could be analyzed because they were represented on the microarrays. The average expression bin was 6.8. With the exception of FAM9C, PDE4B, and TSRC1 (average expression bins, 0.7, 3.3, and 4.66, respectively), 11 of 14 genes associated with CISs of 3 or more integrants were found to be in the highest quartile of expression (average expression bin, 7.1). LMO2, PTPRC, TOMM20, PRKCBP1, and RUNX1 were among the 10% of genes with highest expression, in bin 9.


To understand the biology of insertional gene transfer in clinical trials, we performed high-throughput insertion site mapping on samples derived from a clinical gene therapy trial for SCID-X1. We compared RIS distribution in circulating mature cell populations from patients who had developed a lymphoproliferative adverse event and those who had not. Overall RIS distribution did not differ between the 2 groups. Both revealed the expected distribution features of retroviral vectors, with a strong preference for gene coding regions and symmetrical accumulation close to the TSS. Similar to that previously reported by Wu et al. for HeLa cells (7) and by Laufs et al. for CD34+ cells (8), the frequency of RISs was more closely related to gene density than to overall chromosome size, most frequently targeting chromosomes 1, 17, and 19.

Compared with the distribution in pretransplant cells, in vivo repopulation and normal function of the corrected T cell pool led to a significant skewing of the RIS distribution. Of all RISs detected in posttransplantation blood samples, 21% were found to be clustered, and a much lower CIS frequency in the CD34+ pre-transplantation sample (7.8%) was observed. The observed changes in RIS distribution indicate that nonrandom selection or other biological effects of insertions in or near CIS genes have strong influence on the in vivo fate of gene-corrected cell clones.

Because the pre- and posttransplantation samples of Pt4 were comparable in size (102 RISs versus 141 RISs) and the CD34+ cell culture conditions were identical to those used on the CD34+ cells that engrafted and produced the T cells, the results of this analysis are adequate. Several mechanisms may account for the differences between insertion distribution profiles in pre- versus posttransplantation samples. First, the majority of cells in the pretransplantation sample have no repopulating ability. Therefore, the insertion site distribution of this population is not completely representative of repopulating cells from which posttransplantation cells derive. Second, posttransplantation CISs were even more frequently found near genes related to cell growth than were posttransplantation RISs. Consequently, integration sites in lymphocytes and their progenitor cells are not only related to the gene expression status at the time of vector entry into the repopulating target cell, but might additionally confer a selective advantage, most likely as a result of gene activation, in gene loci that govern growth and/or survival of CD34+ cells and T cell precursors.

This observation was further corroborated by our analysis of whether the catalog of gene-associated insertions correlated with the target cells’ gene expression pattern. In samples obtained after transplantation, there was an even higher correlation among the level of gene expression present in CD34+ cells, the population initially targeted by the transduction, and the RIS frequency than in the analyzed pretransplant sample. The relevance of this association and its influence on clonal selection of engrafted cells is obvious in CISs with 3 or more RISs, where nearly 80% of CISs affect genes of the highest expression quartile in the engrafted gene-corrected cells.

The results of our GO analysis provide further strong evidence that the biological function of genes at the insertion site is related to the in vivo fate of cell clones. When grouping vector-targeted genes according to their role in cellular physiology, engrafted cells show a clear preponderance of RISs located in or near growth-promoting genes, in particular genes revealing kinase and transferase activity. This feature was not seen with the pretransplant samples, indicating that in vivo selection of clones having integrants in or near growth-promoting genes occurred in our patients.

In line with this observation, more than two-thirds of the detected CIS genes were related to cell signaling and growth regulation or control of cell cycle, tyrosine kinases, or differentiation. The most frequent CIS-associated genes — CCND2, a cyclin found deregulated in a number of human cancer cells (27, 28); ZNF217, a zinc finger transcription factor hyperexpressed in solid tumors (29); and LMO2, a T-ALL related protooncogene (30) — are well known to influence clonal proliferation and survival if activated. Together, these areas represent 3% of all clones but only 7 × 10–7% of the genetic code. Aberrant expression in many of these CIS genes in the context of other genetic changes has been linked to human oncogenesis. However, while the presence of CISs indicates that such clones engrafted and/or grew better than others, no evidence of clonal dominance has been detectable in the analyzed samples.

In a T cell gene transfer trial, RIS distribution was similar between clinical in vivo and experimental in vitro samples (14). To test whether pretransplant RIS distribution would have discernible characteristics related to a later lymphoproliferation event, we studied the integration sites in the CD34+ cell population cryopreserved immediately after the transduction phase for Pt4, the first patient who developed a LMO2-associated T-ALL–like disease. No LMO2 RISs, and a low number of CISs, were found among the 102 sequences analyzed in CD34+ cells by LAM-PCR. In contrast, CISs were as frequent in posttransplantation T cells of Pt4 as in those of the other patients, with CCND2-related insertions being the most frequent CISs in this patient. In addition, no LMO2 was detected in a second SCID-X1 trial. The results are published as a related manuscript by Schwarzwaelder et al. (31). Our findings support the concept that insertional activation of CIS genes, even when providing a subtle selective advantage to transduced precursors, will not lead to uncontrolled proliferation in the absence of other genetic changes.

This latter hypothesis is compatible with our recent observation of clonal myeloid cell expansion in a clinical retroviral vector–based gene therapy trial to correct chronic granulomatous disease. We found that a nonrandom integration site distribution had developed by extensive expansion of progenitor cells with MDS1/EVI1-, PRDM16-, and SETBP1-related integration sites in 2 patients. Expression of these genes conferred a selective advantage to the transduced myeloid cells, leading to a 3- to 4-fold self-limiting expansion of the gene-corrected cell fraction (19). Subsequent to the submission of this manuscript, a fourth case of T-monoclonal lymphoproliferation occurred in our group of patients. This lymphoproliferation is under investigation.

Our data indicate that the retrovirus vector integration pattern in T cells following clinical gene transfer is nonrandomly distributed, correlates well with CD34+ target cell gene expression, and is characterized by highly significant clustering into multiple different CISs. These CISs preferentially map to growth-regulating genes expressed in CD34+ cells, highlighting that their integration occurs preferentially in active gene loci and that maintaining their activation in later cell generations by insertion in vector-targeted genes themselves or in the regulatory gene regions likely confers a clonal selection advantage compared with other sites that are rarely affected. Furthermore, the expression as such, but not the intensity of expression, might be influential on insertion. Vector integration in many different sites in our clinical SCID-X1 study has actively influenced the fate of corrected cell clones in vivo. Potential therapeutic advantages associated with the preferential growth of particular clones over time will be the subject of further investigation. Additional biosafety measures designed into vectors could include inactivation of the 3′ long-terminal repeat (3′LTR) enhancer activity, e.g., by use of retrovirus or lentivirus self-inactivating vectors and insulators. Thus, the prospects are excellent that it will be possible in the future to develop safety measures for gene therapy of severe immunodeficiencies, cancer, and other diseases with limited therapeutic options that avoid or at least minimize unwanted gene activation. The excellent therapeutic success achieved in gene therapy trials can be maintained, while the probability of insertional side effects is substantially decreased.


Patients’ cells.

Blood samples were obtained at various time points from patients enrolled in the SCID-X1 gene therapy trial (32). CD3 T cells, CD19 B cells, and CD14 monocytes were selected from patients’ PBMCs by immunomagnetic columns (Miltenyi Biotec). Granulocytes (CD15) were sorted by fluorescence-activated cell sorting (BD). A CD34+ cell sample from Pt4 was separated just prior to reinfusion. Genomic DNA was isolated from all cells using commercially available DNA isolation kits (Qiagen). Informed consent was obtained from parents, and the study was approved by the Comité Consultatif de Protection des Personnes dans la Recherche Biomedicale (CCPPRB), Hôpital Cochin, Paris, France.

Integration site analysis by LAM-PCR.

DNA derived from patients’ blood cells (1–100 ng) were used for integration site sequencing as previously described (21). Biotinylated primers LTRIa (5′-TGCTTACCACAGATATCCTG-3′) and LTRIb (5′-ATCCTGTTTGGCCCATATTC-3′) were used for the preamplification of the vector-genome junctions. After magnetic capture, hexanucleotide priming, and a restriction digest with Tsp509I, a linker cassette was ligated at the 5′ end of the genomic sequence. First exponential amplification of the vector-genome junction was performed with linker cassette primer LCI and vector LTR-specific primer LTRII, followed by second exponential PCR with primers LCII and LTRIII (22, 23). LAM-PCR amplicons were purified, shotgun cloned into the TOPO TA vector (Invitrogen), and sequenced (GATC Biotech and Centre National de Sequencage). Alignment of the integration sequences to the human genome was carried out using the University of California Santa Cruz (UCSC) BLAT genome browser ( The UCSC and Ensembl database ( was used to study the relation to annotated genome features. Unmappable sequences were either too short (<20 kbp) or showed no definitive hit or multiple hits on the human genome.

Definition of CISs and statistics.

For the determination of CISs, we measured the distance between individual integrants independently of being located inside or outside of gene coding regions. We considered 2, 3, or 4 insertions as CISs if they fell within a 30-kbp, 50-kbp, or 100-kbp window from each other, respectively. Of note, 3 clusters of 5, 8, and 9 integrants (next RefSeq gene, LMO2, ZNF217, and CCND2) covered 40 kbp, 170 kbp, and 60 kbp of genomic DNA, respectively. The genomic window for CISs of fifth order and higher was set to 200 kbp.

Computer simulations (10,000 runs) on the haploid size of the human genome (3.12 × 109 kbp) were performed to calculate the likelihood of random, coincidental insertions. We counted the number of CISs of second order formed by 2 integrants within a 30-kbp window, the number of CISs of third order formed by 3 integrants within a 50-kbp window, the number of CISs of fourth order formed by 4 integrants within a 100-kbp window, and the number of CISs of higher orders within a 200-kbp window. Of note, CISs of different orders were analyzed independently of each other, e.g., CISs formed by 3 integrants located within 20 kbp were counted as 3 CISs for the calculation of CISs of second order and as 1 CIS for the calculation of CISs of third order (Supplemental Tables 2 and 3).

Transcription profile in CD34+ cells.

G-CSF–mobilized peripheral blood CD34+ cells from 3 donors were cultured using the same conditions as performed in the original gene therapy trial (1) and served as 3 independent and individual sample sources for further RNA expression analysis. RNA was isolated using Tri Reagent (Sigma-Aldrich) according to the manufacturer’s protocol. The mRNA expression levels were determined using Affymetrix U133 Plus 2.0 arrays and normalized as described previously (33). The normalized microarray values were sorted upwardly on expression and divided into 10 equal-sized expression level categories, designated 0 through 9. The presence of the gene closest to a vector integration site as identified by LAM-PCR analysis was determined in each expression level category. A Cochran-Armitage test for trend was performed to determine whether higher expression level categories corresponded to larger numbers of insertions (34). For all gene symbols on the array, the highest expression values were used to describe the gene expression.

GO analysis.

To classify vector targeted genes according to GO terms, we analyzed RefSeq genes that were hit by vector or had vector integration in the surrounding 10-kbp genomic region. GO analysis was performed using the publicly available EASE software from NIH-DAVID ( The database sorts the genes in categories according to GO terms regarding their “molecular function,” “biological process,” and “cellular compartment.” The gene categories are divided in different levels. Level 1 is a rather general category; this group is composed of many genes. The higher the level, the more precise the parameters, and the more specific the function of its genes. With a level of 3 or 4 there will be a good balance between the amount of listed hits and sufficient specificity. Genes of a higher level category also belong to categories of a lower level. The analysis compares which gene categories were detected more frequently than others compared with their likelihood of detection if insertion was distributed evenly across the entire human genome. Overrepresented gene categories were determined by Fisher exact test. An overrepresentation was given for P values less than 0.05 compared with the whole human genome as a background.

Supplementary Material

Supplemental data:


Funding was provided by the European Commission (5th and 6th Framework Programs, Contracts QLK3-CT-2001-00427-INHERINET and LSHB-CT-2004-005242-CONSERT), by NIH grant R01 CA 112470-01, by Deutsche Forschungsgemeinschaft (DFG) grants Ka976/5-3 and Ka976/6-2, by INSERM, l’Assistance Publique des Hôpitaux de Paris (AP-HP), and by Agence Nationale de la Recherche (ANR) grant 05-MRAR.004.


Nonstandard abbreviations used: γc, common γ chain; CIS, common integration site; GO, gene ontology; kbp, kilobase pair(s); LAM-PCR, linear amplification–mediated PCR; LTR, long-terminal repeat; MLV, murine leukemia virus; Pt, patient; RIS, retroviral integration site; SCID-X1, X-linked SCID; TSS, transcription start site.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 117:2225–2232 (2007). doi:10.1172/JCI31659

Annette Deichmann, Salima Hacein-Bey-Abina, Manfred Schmidt, and Alexandrine Garrigue contributed equally to this work.

Christof von Kalle and Marina Cavazzana-Calvo are co–senior authors.

See the related Commentary beginning on page 2083.


1. Cavazzana-Calvo M., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669–672. [PubMed]
2. Aiuti A., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–2413. [PubMed]
3. Gaspar H.B., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364:2181–2187. [PubMed]
4. Coffin, J.M., Hughes, S.H., and Varmus, H.E. 1997.Retroviruses . Cold Spring Harbor Laboratory Press. Plainview, New York, USA. 843 pp.
5. Moolten F.L., Cupples L.A. A model for predicting the risk of cancer consequent to retroviral gene therapy. Hum. Gene Ther. 1992;3:479–486. [PubMed]
6. Schröder A.R., et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110:521–529. [PubMed]
7. Wu X., Li Y., Crise B., Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300:1749–1751. [PubMed]
8. Laufs S., et al. Retroviral vector integration occurs in preferred genomic targets in human bone marrow repopulating cells. Blood. 2003;101:2191–2198. [PubMed]
9. Mitchell R.S., et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004;2:e234. [PMC free article] [PubMed]
10. Mooslehner K., Karls U., Harbers K. Retroviral integration sites in transgenic Mov mice frequently map in the vicinity of transcribed DNA regions. J. Virol. 1990;64:3056–3058. [PMC free article] [PubMed]
11. Scherdin U., Rhodes K., Breindl M. Transcriptionally active genome regions are preferred targets for retrovirus integration. J. Virol. 1990;64:907–912. [PMC free article] [PubMed]
12. Bushman F.D. Targeting survival: integration site selection by retroviruses and LTR-retrotransposons. Cell. 2003;115:135–138. [PubMed]
13. Maxfield L.F., Fraize C.D., Coffin J.M. Relationship between retroviral DNA-integration-site selection and host cell transcription. Proc. Natl. Acad. Sci. U. S. A. 2005;102:1436–1441. [PubMed]
14. Recchia A., et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc. Natl. Acad. Sci. U. S. A. 2006;103:1457–1462. [PubMed]
15. Hematti P., et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. . 2004;2:e423. [PMC free article] [PubMed]
16. Du Y., Jenkins N.A., Copeland N.G. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood. 2005;106:3932–3939. [PubMed]
17. Kustikova O., et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science. 2005;308:1171–1174. [PubMed]
18. Calmels B., et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood. 2005;106:2530–2533. [PubMed]
19. Ott M.G., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 2006;12:401–409. [PubMed]
20. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415–419. [PubMed]
21. Schmidt M., et al. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. . Blood. 2005;105:2699–2706. [PubMed]
22. Schmidt M., et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood. . 2002;100:2737–2743. [PubMed]
23. Schmidt M., et al. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. . Nat. Med. . 2003;9:463–468. [PubMed]
24. Mikkers H., et al. High-throughput retroviral tagging to identify components of specific signalling pathways in cancer. Nat. Genet. 2002;32:153–159. [PubMed]
25. Lund A.H., et al. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat. Genet. 2002;32:160–165. [PubMed]
26. Suzuki T., et al. New genes involved in cancer identified by retroviral tagging. Nat. Genet. 2002;32:166–174. [PubMed]
27. von Eyben F.E. Chromosomes, genes, and development of testicular germ cell tumors. Cancer Genet. Cytogenet. 2004;151:93–138. [PubMed]
28. Hideshima T., Bergsagel P.L., Kuehl W.M., Anderson K.C. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607–618. [PubMed]
29. Collins C., et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res. 2001;11:1034–1042. [PubMed]
30. Nam C.H., Rabbitts T.H. The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. Mol. Ther. 2006;13:15–25. [PubMed]
31. Schwarzwaelder K., et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J. Clin. Invest. 2007;117:2241–2249. doi: 10.1172/JCI31661. [Cross Ref]
32. Hacein-Bey-Abina S., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. . 2002;346:1185–1193. [PubMed]
33. Dik W.A., et al. New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J. Exp. Med. 2005;201:1715–1723. [PMC free article] [PubMed]
34. Armitage, P., Berry, G., and Matthews, J.N.S. 2001. Statistical methods in medical research. 4th edition. Blackwell Publishing. Malden, Massachusetts, USA/Oxford, United Kingdom. 832 pp.

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation